ONO-8130 是一种口服有效且选择性的前列腺素 EP1 受体 (EP1 receptor) 拮抗剂,可阻断 L6 脊髓中 ERK 的磷酸化,减轻环磷酰胺致膀胱炎小鼠的膀胱疼痛,并可用于间质性膀胱炎的研究。
产品编号: MS-Y99831 CAS No.: 459841-96-4 分子式: C25H28N2O5S2 分子量: 500.63
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

ONO-8130 是一种口服有效且选择性的前列腺素 EP1 受体 (EP1 receptor) 拮抗剂,可阻断 L6 脊髓中 ERK 的磷酸化,减轻环磷酰胺致膀胱炎小鼠的膀胱疼痛,并可用于间质性膀胱炎的研究。

生物实验数据

生物活性 ONO-8130 is an orally effective and selective prostaglandin EP1 receptor (EP1 receptor) antagonist that blocks ERK phosphorylation in the L6 spinal cord, alleviates bladder pain in cyclophosphamide-induced cystitis mice, and can be used for research on interstitial cystitis.
体内研究
(In Vivo)

ONO-8130 (0.3-30 mg/kg; Oral preadministration, once) strongly prevents both the bladder pain-like behavior and referred hyperalgesia in a dose-dependent manner.
ONO-8130 (30 mg/kg; Orally, once) reverses the established cystitis-related bladder pain.
ONO-8130 (30 mg/kg; Orally, once) strongly inhibits phosphorylation of ERK in MDH, DCM, and SPN of the L6 spinal cord caused by intravesical administration of PGE2.

Animal Model: Female ddY mice (18-22 g, 4-5 weeks old)
Dosage: 0.3, 3, 10, and 30 mg/kg
Administration: Orally, once
Result: Strongly prevented both the bladder pain-like behavior and referred hyperalgesia in a dose-dependent manner, but had slight effect on the increased bladder weight and vascular permeability.
Animal Model: Female ddY mice (18-22 g, 4-5 weeks old, established bladder pain caused by IP cyclophosphamide)
Dosage: 10, 30 mg/kg
Administration: Orally, once (administered 2.75 hours after i.p. cyclophosphamide)
Result: Markedly attenuated the bladder pain-like nociceptive behavior and referred hyperalgesia in the acute phase (3.5-4 h after cyclophosphamide).
Animal Model: Female ddY mice (18-22 g, 4-5 weeks old, established bladder pain caused by IP cyclophosphamide)
Dosage: 30 mg/kg
Administration: Orally, once (administered 4.75 hours after i.p. cyclophosphamide)
Result: Significantly suppressed the bladder pain-like nociceptive behavior and tended to reduce the referred hyperalgesia in the persistent phase, 5.5-6 hours after cyclophosphamide.
Animal Model: Female ddY mice (18-22 g, 4-5 weeks old, intravesical administration of PGE2 at 5 nmol/mouse)
Dosage: 30 mg/kg
Administration: Orally, once
Result: Strongly inhibited phosphorylation of ERK in MDH, DCM, and SPN of the L6 spinal cord caused by intravesical administration of PGE2 at 5 nmol/mouse, exerted complete blockade in DCM, while its inhibitory effects in MDH and SPN were partial.

化学信息

分子量 500.63
分子式 C25H28N2O5S2
CAS No. 459841-96-4

储存&溶解度

溶解度信息
DMSO: 5.01 mg/mL (10.01 mM), Sonication is recommended.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础